Nephrol Dial Transplant (2003) 18: 10-13
© 2003 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?
Department of Medicine, Division of Nephrology and Department of Clinical Pharmacology, University Hospital Groningen, The Netherlands
Keywords: end-stage renal failure; general population; microalbuminuria; screening
| The first 150 words of the full text of this article appear below. |
Introduction
The number of patients taken into renal replacement therapy programmes has gradually increased over the last decades. This may partly be due to improvements in dialysis techniques and a better availability of these programmes. However, the pattern of the cause of end-stage renal failure also has been changing over time. In the 1970s glomerulonephritis and pyelonephritis were the most prevalent causes for enrolment into renal replacement programmes. In the last decade the prevalence of these diseases diminished and increasingly end-stage renal failure was due to diabetes, predominantly type II, and renal vascular diseases such as hypertension and generalized atherosclerosis. Several reasons have been put forward to explain this change. First, and possibly most important, the incidence of diseases has been changing. In addition, the age of patients entering end-stage renal failure programmes increased progressively, and patients with atherosclerotic cardiovascular disease survive cardiac events and reach the stage of atherosclerotic end-stage
Factors associated with progressive renal failure in subjects with known pre-existing renal disease
Detection of subjects at risk for progressive renal function loss in the general population
The PREVEND study
Microalbuminuria and renal function in the general population
Microalbuminuria versus renal and cardiac prognosis
Conclusions
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Dobre, H. J. Lambers Heerspink, and D. de Zeeuw Reducing cardiovascular risk: protecting the kidney Eur. Heart J. Suppl., December 1, 2009; 11(suppl_F): F39 - F46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Domrongkitchaiporn, P. Sritara, C. Kitiyakara, W. Stitchantrakul, V. Krittaphol, P. Lolekha, S. Cheepudomwit, and T. Yipintsoi Risk Factors for Development of Decreased Kidney Function in a Southeast Asian Population: A 12-Year Cohort Study J. Am. Soc. Nephrol., March 1, 2005; 16(3): 791 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Dyer, P. Greenland, P. Elliott, M. L. Daviglus, G. Claeys, H. Kesteloot, H. Ueshima, J. Stamler, and for the INTERMAP Research Group Evaluation of Measures of Urinary Albumin Excretion in Epidemiologic Studies Am. J. Epidemiol., December 1, 2004; 160(11): 1122 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Ruilope New European guidelines for management of hypertension: what is relevant for the nephrologist Nephrol. Dial. Transplant., March 1, 2004; 19(3): 524 - 528. [Full Text] [PDF]
|
|